{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:08:40Z","timestamp":1792613320082,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmogo.2025.100274","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:24:46Z","timestamp":1765826686000},"page":"100274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)"],"prefix":"10.1016","volume":"11","author":[{"given":"B.","family":"Kimmel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.T.","family":"L\u00f6hnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-1179","authenticated-orcid":false,"given":"F.","family":"Wedekink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5091-5060","authenticated-orcid":false,"given":"M.","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-9034","authenticated-orcid":false,"given":"S.","family":"Ormanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hartlapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-2127","authenticated-orcid":false,"given":"S.","family":"Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Alg\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5575-1010","authenticated-orcid":false,"given":"F.","family":"Kullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ettrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4983-8424","authenticated-orcid":false,"given":"F.","family":"Anger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-T.","family":"Germer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-4297","authenticated-orcid":false,"given":"J.","family":"Wischhusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kunzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.esmogo.2025.100274_bib1","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.esmogo.2025.100274_bib2","first-page":"2140","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100274_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100274_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","author":"Philip","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"30","key":"10.1016\/j.esmogo.2025.100274_bib5","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO-24-01502","article-title":"Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: the randomized CONKO-007 trial","volume":"43","author":"Fietkau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmogo.2025.100274_bib6","doi-asserted-by":"crossref","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","article-title":"MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily","volume":"94","author":"Bootcov","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100274_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.65.1.2","article-title":"MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation","volume":"65","author":"Fairlie","year":"1999","journal-title":"J Leukoc Biol"},{"issue":"7","key":"10.1016\/j.esmogo.2025.100274_bib8","first-page":"2642","article-title":"MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma","volume":"9","author":"Brown","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100274_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cytogfr.2013.05.003","article-title":"The multiple facets of the TGF-\u03b2 family cytokine growth\/differentiation factor-15\/macrophage inhibitory cytokine-1","volume":"24","author":"Unsicker","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.esmogo.2025.100274_bib10","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","article-title":"Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint","volume":"11","author":"Wischhusen","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100274_bib11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3233\/CBM-170203","article-title":"Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass","volume":"21","author":"Hogendorf","year":"2018","journal-title":"Cancer Biomark"},{"issue":"19","key":"10.1016\/j.esmogo.2025.100274_bib12","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.3390\/cancers13194842","article-title":"Clinical and tumor characteristics of patients with high serum levels of growth differentiation factor 15 in advanced pancreatic cancer","volume":"13","author":"Suzuki","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmogo.2025.100274_bib13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/1471-2407-14-578","article-title":"Macrophage inhibitory cytokine 1 (MIC-1\/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Cancer"},{"issue":"21","key":"10.1016\/j.esmogo.2025.100274_bib14","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1158\/1078-0432.CCR-08-3126","article-title":"Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer","volume":"15","author":"Brown","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.esmogo.2025.100274_bib15","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-03-0165","article-title":"Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers","volume":"10","author":"Koopmann","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100274_bib16","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1073\/pnas.0530278100","article-title":"Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum","volume":"100","author":"Welsh","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100274_bib17","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1038\/s41467-023-39817-3","article-title":"Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment","volume":"14","author":"Haake","year":"2023","journal-title":"Nat Commun"},{"issue":"8048","key":"10.1016\/j.esmogo.2025.100274_bib18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","article-title":"Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours","volume":"637","author":"Melero","year":"2025","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.esmogo.2025.100274_bib19","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100274_bib20","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jalm\/jfac055","article-title":"The common H202D variant in GDF-15 does not affect its bioactivity but can significantly interfere with measurement of its circulating levels","volume":"7","author":"Karusheva","year":"2022","journal-title":"J Appl Lab Med"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100274_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41416-023-02295-x","article-title":"TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer","volume":"129","author":"Guenther","year":"2023","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.esmogo.2025.100274_bib22","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.jid.2016.07.016","article-title":"High GDF-15 serum levels independently correlate with poorer overall survival of patients with tumor-free stage III and unresectable stage IV melanoma","volume":"136","author":"Weide","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100274_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100552","article-title":"Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)","volume":"7","author":"Hartlapp","year":"2022","journal-title":"ESMO Open"},{"issue":"14","key":"10.1016\/j.esmogo.2025.100274_bib24","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3748\/wjg.v26.i14.1660","article-title":"Macrophage inhibitory cytokine-1\/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort","volume":"26","author":"O\u2019Neill","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100274_bib25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cmet.2020.10.023","article-title":"GDF-15 Neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates","volume":"32","author":"Breen","year":"2020","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100274_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115372","article-title":"Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage","volume":"10","author":"Altena","year":"2015","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.esmogo.2025.100274_bib27","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.3390\/ijms21165766","article-title":"Cellular responses to platinum-based anticancer drugs and UVC: role of p53 and implications for cancer therapy","volume":"21","author":"Murray","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100274_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036594","article-title":"Growth differentiation factor-15 may be a novel biomarker in pancreatic cancer: a review","volume":"103","author":"Guo","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100274_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10439-018-1997-7","article-title":"Solid stress facilitates fibroblasts activation to promote pancreatic cancer cell migration","volume":"46","author":"Kalli","year":"2018","journal-title":"Ann Biomed Eng"},{"issue":"12","key":"10.1016\/j.esmogo.2025.100274_bib30","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.humimm.2021.06.007","article-title":"Roles and regulation of growth differentiation factor-15 in the immune and tumor microenvironment","volume":"82","author":"Lodi","year":"2021","journal-title":"Hum Immunol"},{"issue":"8","key":"10.1016\/j.esmogo.2025.100274_bib31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/0008-5472.CAN-24-0086","article-title":"Fibroblasts in the aged pancreas drive pancreatic cancer progression","volume":"84","author":"Zabransky","year":"2024","journal-title":"Cancer Res"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825001438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825001438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:07:02Z","timestamp":1775315222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819825001438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"alternative-id":["S2949819825001438"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100274","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100274"}}